A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5% in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Trial Profile

A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5% in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Streptococcal infections
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms PANS
  • Most Recent Events

    • 05 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 24 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top